Ngomhlaka-21 Ephreli 2026, i-Center for Drug Evaluation (CDE) ye-National Medical Products Administration yamemezela ukuthi i-HS-20093 yomjovo (risvutatug rezetecan) iqokwe njengomuntu ozongenela i-Breakthrough Therapy yokwelapha iziguli ezinomdlavuza we-prostate omelana nomdlavuza we-prostate osezingeni eliphezulu oye wathola ukwelashwa okusha kwamahomoni kanye ne-chemotherapy esekelwe ku-taxane. Lezi zindaba ziletha ithemba elisha ezigulini ezinomdlavuza we-prostate emhlabeni jikelele.
I-HS-20093 (HS-20093 / GSK5764227) iyi-conjugate ye-antibody-drug eqondisa i-B7-H3 (ADC) ethuthukiswe ngokuzimela yi-Hansoh. Ku-2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026), imiphumela evela esivivinyweni seSigaba II esivulekile, esinezikhungo eziningi esibizwa ngokuthi i-ARTEMIS-003 (NCT06001255) yethulwe ngokusemthethweni. Ucwaningo luhlole ukusebenza kahle nokuphepha kwe-HS-20093 ezigulini ezinomdlavuza we-prostate omelana nomdlavuza we-prostate (mCRPC) osakazeke ngemuva kokwelashwa okungenani okukodwa kwangaphambilini.
Imiphumela yayikhuthaza:
- **Ezigulini ezelashwe nge-taxanes ngaphambilini:** izinga lokuphendula eliqondile (i-cORR) eliqinisekisiwe lalingu-38.9%, kanti izinga lokuphendula le-prostate-specific antigen (PSA) (≥50% ukwehla) lalingu-40.7%.
- **Ezigulini ezingazange zelashwe nge-taxanes ngaphambilini:** izinga lokuphendula okuqondile elingakaqinisekiswa (uORR) lalingu-41.7%, kanti izinga lokuphendula le-PSA50 lalingu-23.8%.
Le mininingwane ikhombisa ukuthi i-HS-20093 ibonisa umsebenzi obalulekile nohlala isikhathi eside wokulwa nomdlavuza kungakhathaliseki ukuthi i-chemotherapy esekwe ku-taxane yayisetshenziswa ngaphambilini. Ezigulini ezinesifo esithuthukile eseziye zamelana noma zaphinde zabuyela emuva ngemva kokunakekelwa okujwayelekile kwamanje (ukwelashwa okusha kwama-hormone + i-chemotherapy), lokhu ngokungangabazeki kumelela inketho entsha newusizo emtholampilo.
**Iziguli zakwamanye amazwe zingaluthola kanjani lolu hlobo lokwelapha olusezingeni eliphezulu?**
Uma wena noma ilungu lomndeni lilwa nomdlavuza we-prostate omelana nokuthenwa okuthuthukile futhi ninganelisekile noma ningabekezeleli izinketho zokwelapha ezikhona, manje ningaxhumana noMnyango Wezwe Lonke Wesibhedlela Se-Beijing South Region Oncology ukuze nihlole ukufaneleka kokwelashwa kwe-HS-20093. Njengesikhungo esikhethekile esikwazi ukuhlinzeka ngezinsizakalo zezokwelapha zomhlaba wonke, uMnyango Wezwe Lonke wesibhedlela uzibophezele ekuhlinzekeni ukunakekelwa okuphelele kwe-oncology ezigulini zomhlaba wonke, okuhlanganisa ukufinyelela ezivivinyweni ezintsha zemitholampilo kanye nokwelashwa okuphumelelayo.
**Xhumana nathi manje:**
- **Inombolo Yocingo:** 400-880-3716
- **I-ID ye-WeChat:** 17801183037
- **I-imeyili:**
① 100085_010@163.com
② myimmnet@163.com
**Amanothi abalulekile:**
- Ngaphambi kokuvakashela, iziguli zakwamanye amazwe kufanele zilungiselele izinguqulo zesiNgisi/isiShayina zamarekhodi ezokwelapha angaphambilini (kufaka phakathi imibiko yezifo, ukuhlolwa kwezithombe, kanye namarekhodi e-chemotherapy yangaphambilini kanye nokwelashwa ngama-hormone) ukuze kube lula ukuhlolwa okusheshayo kodokotela.
- UMnyango wethu Wamazwe Ngamazwe ungasiza ngezincwadi zesimemo se-visa yezokwelapha, ama-aphoyintimenti, kanye nezinsizakalo zokuhumusha. Ukuze uthole imibuzo ethile, sicela usithinte ngeziteshi ezingenhla.
Isikhathi sokuthunyelwe: Ephreli-28-2026